Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical

Abstract excerpt

Oncogenic fusion proteins, arising from chromosomal rearrangements, have emerged as prominent drivers of tumorigenesis and crucial therapeutic targets in cancer research. In recent years, the potential of small molecular inhibitors in selectively targeting fusion proteins has exhibited significant prospects, offering a novel approach to combat malignancies harboring these aberrant molecular entities. This review...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors
• Share to Ubiquitin and proteasome pathways